BIOMAT Database Logo BIOMAT Database Logo

Decreased urinary taurine in essential hypertension. 1983

N Kohashi, and T Okabayashi, and J Hama, and R Katori

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013654 Taurine A conditionally essential nutrient, important during mammalian development. It is present in milk but is isolated mostly from ox bile and strongly conjugates bile acids. Taufon,Tauphon,Taurine Hydrochloride,Taurine Zinc Salt (2:1),Taurine, Monopotassium Salt

Related Publications

N Kohashi, and T Okabayashi, and J Hama, and R Katori
Decrease of urinary taurine in essential hypertension.
January 1983, Japanese heart journal,
N Kohashi, and T Okabayashi, and J Hama, and R Katori
Increased urinary cGMP and decreased albumin excretion with isradipine treatment in essential hypertension.
November 1997, Cardiovascular drugs and therapy,
N Kohashi, and T Okabayashi, and J Hama, and R Katori
Decreased peripheral dopaminergic activity in essential hypertension?
February 1983, Scandinavian journal of clinical and laboratory investigation,
N Kohashi, and T Okabayashi, and J Hama, and R Katori
Decreased central dopaminergic activity in essential hypertension.
April 1987, Journal of hypertension,
N Kohashi, and T Okabayashi, and J Hama, and R Katori
Decreased beta-adrenoceptors in polymorphonucleates in essential hypertension.
September 1981, Bollettino della Societa italiana di biologia sperimentale,
N Kohashi, and T Okabayashi, and J Hama, and R Katori
Urinary beta-thromboglobulin in essential hypertension.
February 1980, British journal of haematology,
N Kohashi, and T Okabayashi, and J Hama, and R Katori
URINARY CONCENTRATING MECHANISM IN ESSENTIAL HYPERTENSION.
June 1965, The American journal of medicine,
N Kohashi, and T Okabayashi, and J Hama, and R Katori
Urinary calcium excretion in essential hypertension.
October 1992, The Journal of laboratory and clinical medicine,
N Kohashi, and T Okabayashi, and J Hama, and R Katori
Urinary normetadrenaline excretion in essential hypertension.
May 1967, Clinica chimica acta; international journal of clinical chemistry,
N Kohashi, and T Okabayashi, and J Hama, and R Katori
Decreased endogenous antioxidant enzymatic status in essential hypertension.
June 2000, Journal of human hypertension,
Copied contents to your clipboard!